Becatecarin

N/A

Report date: 2024/04/18 14:32:46
NME

Base Information

Drug NameBecatecarin
Drug Alias Name贝特卡令becatecarina贝克卡林becatecarinumDEAE-rebeccamycin +[14] 
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionDNA topoisomerase inhibitors
TargetsDNA topoisomerase
Therapy Area/IndicationsCNS Embryonal TumorSolid tumoursMyelodysplastic Syndromes +[25] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryBelgiumCanadaUnited States +[16] 
CombinationsNo
Global Highest StatusDiscontinued (Phase 3 Clinical)
Highest Status in ChinaN/A
Originator CompaniesBristol-Myers Squibb Company
China Registration ClassN/A

Develop Information

Active CompaniesN/A
Inactive CompaniesBarbara Ann Karmanos Cancer InstituteNational Cancer InstituteNorthwestern University +[4] 
Active IndicationsN/A
Inactive IndicationsCNS Embryonal TumorSolid tumoursMyelodysplastic Syndromes +[25] 

Other Information

ATC CodeN/A
Related LinksKEGG